|

PD-L1 t-haNK cells Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 2: 1

Top Sponsors

  • National Cancer Institute (NCI)1

Indications

  • Stage IV Squamous Cell Carcinoma of the Head and Neck1
  • Stage III Squamous Cell Carcinoma of the Head and Neck1
  • Stage II Squamous Cell Carcinoma of the Head and Neck1
  • Cancer1

Bethesda, Maryland1 trial

Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell Carcinoma

National Institutes of Health Clinical Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.